2005
Combination of Cisplatin and Raltitrexed Improves Survival with Mesothelioma
According to the results of a phase III clinical trial published in the Journal of Clinical Oncology, treatment with both cisplatin and raltitrexed results in better survival among patients with malignant pleural mesothelioma than treatment with cisplatin alone.
Fujirebio Diagnostics Expands Commercial Availability of First Blood Test for Mesothelioma
Fujirebio Diagnostics, Inc. (FDI), a world-leader in oncology testing, and Cisbio international, a French biotechnology company, today announced a distribution agreement for European distribution of FDI's new blood test for mesothelioma - MESOMARK(TM).
SV40 not implicated in Mesothelioma
New highly sensitive approach shows no evidence of SV40 in tumors - SV40 unlikely to be factor in asbestos related cancers...
